Actively Recruiting
Open-label Study to Evaluate GSK5471713 Dose and Safety in Adult Men With Metastatic Castration-Resistant Prostate Cancer
Led by GlaxoSmithKline · Updated on 2026-10-28
54
Participants Needed
20
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GSK5471713 as a new treatment for adult men with metastatic castration-resistant prostate cancer mCRPC. This first-time-in-human study aims to assess the safety, tolerability, how the drug moves through and affects the body, and to understand the potential benefits and risks of using GSK5471713 alone in this advanced prostate cancer. Participants will receive GSK5471713 at different dose levels based on a dose escalation design to find the appropriate dose. The study is open-label and includes dose escalation and dose optimization phases. Treatment is given according to the assigned dose level, with monitoring for any dose limiting toxicities or adverse events throughout the study. During the trial, participants will be closely monitored for safety through tracking of side effects, serious adverse events, and any dose changes needed. Researchers will also measure blood levels of the drug and evaluate prostate cancer responses using prostate-specific antigen PSA levels and tumor response assessments. The study will last for approximately 45 months with ongoing assessments, safety monitoring, and evaluation of clinical activity.
CONDITIONS
Brief Title
First-Time-in-Human Study of GSK5471713 in Adults With mCRPC
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here